Purpose: To evaluate the safety and efficacy of intravitreal diclofenac sodium.
Methods: A 61-year-old male with persistent diabetic macular edema was treated with 450 μg of intravitreal diclofenac sodium (systemic preparation).
Results: Postinjection Day 1, the spectral domain optical coherence tomography showed irregular vitreoretinal interface with wrinkling and separation of the internal limiting membrane from the nerve fiber layer with homogeneity of the inner layers. At 1 month, the compactness of the retinal layers was restored. Complete resolution of the cystoid macular edema was seen. At 1 year, there was mild flattening of the foveal depression with epiretinal membrane.
Conclusion: Various studies have shown the safety and efficacy of intravitreal diclofenac without any reported side effect. We report the inner retinal toxicity in the form of cystic spaces and splitting of internal limiting membrane from nerve fiber layer on the first follow-up day, postinjection, which resolved over a period of 1 month. Further studies are needed to assess the safety of intravitreal diclofenac sodium.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICB.0000000000000484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COMPARISON OF THE EFFECTS OF EIGHT DIFFERENT TOPICAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON REDUCING INTRAVITREAL INJECTION-INDUCED PAIN.
Retina
July 2024
Trakya University School of Medicine, Department of Ophthalmology, Edirne, Turkey; and.
Purpose: To compare topical nonsteroidal anti-inflammatory drug (NSAID) efficacy on intravitreal injection-induced pain reduction and determine the most efficient topical NSAID.
Methods: This randomized-controlled study included 662 eyes of 662 patients. Based on the types of NSAID administered before intravitreal injection, eight subgroups were formed.
Non-steroidal intravitreal injection for noninfectious uveitic cystoid macular edema: Systematic review and meta-analysis.
Eur J Ophthalmol
September 2024
Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
Purpose: To systematically review the published manuscripts on the non-steroidal intravitreal injection for treatment of noninfectious uveitic cystoid macular edema (CME).
Methods: The PubMed, Scopus, and Web of Science, Science Direct, ProQuest, Cochrane Library, ProQuest, Embase, Clinical Key, and Springer were searched for relevant articles published until May 2022. The random-effects models were used to estimate the mean difference (MD) and 95% confidence interval (CI) for postoperative central macular thickness (CMT) and visual acuity (VA) changes.
Post-Intravitreal injection pain reduction using topical NSAIDS: A comparative study.
Eur J Ophthalmol
September 2023
Department of Ophthalmology, Meir Medical Center, Kfar Saba, Israel.
Purpose: To compare the efficacy of two different topical non-steroidal anti-inflammatory drugs (NSAIDs) drops with versus without conservatives after intravitreal injections (IVIs).
Design: Prospective, randomized, placebo-controlled, single-blinded comparative study.
Participants And Method: A total of 308 eyes of 252 patients receiving an IVI of anti-vascular endothelial growth factor (anti-VEGF) were randomly assigned to receive either a single drop of nepafenac 0.
Topical Nonsteroidal Anti-inflammatory Drugs for Pain Resulting from Intravitreal Injections: A Meta-Analysis.
Ophthalmol Retina
May 2020
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address:
Topic: The role of topical nonsteroidal anti-inflammatory drugs (NSAIDs) for the reduction of ocular pain after intravitreal injections (IVIs) has been explored. To provide clarity on the evidence for these agents, the present meta-analysis of randomized controlled trials (RCTs) was undertaken.
Clinical Relevance: No standard of care regimen exists for the management of pain resulting from IVIs.
Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies.
Clin Ophthalmol
August 2019
Cornea and Cataract Service, Florida Eye Microsurgical Institute, Boynton Beach, FL, USA.
Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat postoperative inflammation and pain following cataract surgery and for treatment and prophylaxis of pseudophakic cystoid macular edema (CME). Bromfenac is a brominated NSAID with strong in vitro anti-inflammatory potency. Like other ophthalmic NSAIDs, bromfenac is often used outside of the cataract surgery setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!